(Q44117309)

English

Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease

scientific article published in September 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Epstein–Barr virus

0 references

author name string

Stephan H Oertel

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Ioannis Anagnostopoulos

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Manfred W Hummel

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sven Jonas

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Hanno B Riess

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

1 September 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1120-1123

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03764.X

21 January 2018

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03764.X

21 January 2018

Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03764.X

21 January 2018

Virostatic therapy for advanced lymphoproliferation associated with the Epstein-Barr virus in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03764.X

21 January 2018

Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03764.X

21 January 2018

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03764.X

21 January 2018

Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03764.X

21 January 2018

Identifiers

10.1046/J.1365-2141.2002.03764.X

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44117309&oldid=2106754078"